Phase-Specific and Lifetime Costs of Multiple Myeloma Among Older Adults in the US
Sign Up to like & getrecommendations! Published in 2021 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.16357
Abstract: Key Points Question What are the incremental lifetime and phase-specific Medicare costs for older adults with multiple myeloma? Findings In this cohort study of data from 4533 patients with multiple myeloma, the incremental lifetime multiple… read more here.
Keywords: cost; multiple myeloma; lifetime; phase specific ... See more keywords
Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.28877
Abstract: Key Points Question Is there equitable geographic access to chimeric antigen receptor–T cells (CAR-T) and bispecific antibodies trials for multiple myeloma in the US? Findings In this cross-sectional study of data from 69 clinical trials… read more here.
Keywords: trials multiple; multiple myeloma; antibodies trials; access chimeric ... See more keywords
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.
Sign Up to like & getrecommendations! Published in 2021 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2021.3971
Abstract: Importance High-risk smoldering myeloma has a 5-year risk of progression to symptomatic multiple myeloma of approximately 75%. Treatment with lenalidomide decreases the risk of progression; however, novel triplet regimens are superior, and earlier disease may… read more here.
Keywords: risk; smoldering myeloma; high risk; multiple myeloma ... See more keywords
Chemotherapy-Induced Hyperopic Surprise in a Woman With Multiple Myeloma.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA ophthalmology"
DOI: 10.1001/jamaophthalmol.2022.3226
Abstract: This case report describes a woman aged 64 years with a history of multiple myeloma who presented with worsening vision after receiving an infusion of belantamab mafodotin. read more here.
Keywords: hyperopic surprise; chemotherapy induced; induced hyperopic; multiple myeloma ... See more keywords
Acute-Onset Orbital Inflammation in a Patient With Multiple Myeloma.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA ophthalmology"
DOI: 10.1001/jamaophthalmol.2023.0021
Abstract: A 72-year-old man presented with right eye conjunctival injection, chemosis, eyelid edema, and pain with eye movements. Examination of the right eye was notable for visual acuity of 20/50, reduced ocular motility in all gazes,… read more here.
Keywords: onset orbital; orbital inflammation; inflammation patient; patient multiple ... See more keywords
Microfluidic enrichment of plasma cells improves treatment of multiple myeloma
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12201
Abstract: Cytogenetic alterations form the basis for risk stratification for multiple myeloma (MM) and guide the selection of therapy; however, current pathology assays performed on bone marrow samples can produce false‐negatives due to the unpredictable distribution… read more here.
Keywords: cytogenetic alterations; multiple myeloma; plasma cells; cd45 ... See more keywords
PINK1‐Dependent Mitophagy Regulates the Migration and Homing of Multiple Myeloma Cells via the MOB1B‐Mediated Hippo‐YAP/TAZ Pathway
Sign Up to like & getrecommendations! Published in 2020 at "Advanced Science"
DOI: 10.1002/advs.201900860
Abstract: Abstract The roles of mitochondrial dysfunction in carcinogenesis remain largely unknown. The effects of PTEN‐induced putative kinase 1 (PINK1)‐dependent mitophagy on the pathogenesis of multiple myeloma (MM) are determined. The levels of the PINK1‐dependent mitophagy… read more here.
Keywords: multiple myeloma; pink1 dependent; dependent mitophagy; myeloma ... See more keywords
Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2022 at "Advanced Science"
DOI: 10.1002/advs.202104491
Abstract: Abstract It has been previously shown that (never in mitosis gene A)‐related kinase 2 (NEK2) is upregulated in multiple myeloma (MM) and contributes to drug resistance. However, the mechanisms behind this upregulation remain poorly understood.… read more here.
Keywords: aberrations interaction; interaction nek2; multiple myeloma; nek2 tp53 ... See more keywords
Delivery of Therapeutic RNA to the Bone Marrow in Multiple Myeloma Using CD38-Targeted Lipid Nanoparticles.
Sign Up to like & getrecommendations! Published in 2023 at "Advanced science"
DOI: 10.1002/advs.202301377
Abstract: Multiple myeloma (MM) is a cancer of differentiated plasma cells that occurs in the bone marrow (BM). Despite the recent advancements in drug development, most patients with MM eventually relapse and the disease remains incurable.… read more here.
Keywords: lipid nanoparticles; bone marrow; cd38; rna ... See more keywords
IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide‐dexamethasone therapy in multiple myeloma
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Hematology"
DOI: 10.1002/ajh.24634
Abstract: Immunomodulatory drugs (IMiDs) are a cornerstone in the treatment of multiple myeloma (MM), but specific markers to predict outcome are still missing. Recent work pointed to a prognostic role for IMiD target genes (e.g. CRBN).… read more here.
Keywords: cell populations; multiple myeloma; expression; lenalidomide dexamethasone ... See more keywords
Causes of early death in multiple myeloma patients treated with high-dose therapy followed by autologous stem cell transplantation: A study based on the nationwide Danish Multiple Myeloma Registry.
Sign Up to like & getrecommendations! Published in 2017 at "American journal of hematology"
DOI: 10.1002/ajh.24857
Abstract: other day for 6 doses. This was followed by a maintenance dose of 120 mg/kg IV weekly for seven weeks in responding patients. Four patients received AAT as the first therapy option after demonstrating steroid-refractory… read more here.
Keywords: therapy; multiple myeloma; steroid refractory; gvhd ... See more keywords